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Abstract: Lifelong persistent infection by herpesviruses depends on the balance between 
host immune responses and viral immune evasion. CD4 T cells responding to antigens 
presented on major histocompatibility complex class II (MHC-II) molecules are known to 
play an important role in controlling herpesvirus infections. Here we review, with emphasis 
on human herpesvirus infections, the strategies evolved to evade CD4 T cell immunity. 
These viruses target multiple points on the MHC class II antigen presentation pathway.  
The mechanisms include: suppression of CIITA to inhibit the synthesis of MHC class II 
molecules, diversion or degradation of HLA-DR molecules during membrane transport, 
and direct targeting of the invariant chain chaperone of HLA-DR. 
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1. Introduction 
Members of the family herpesviridae are large DNA viruses that commonly cause disease in 
animals. In humans, eight distinct viruses have been identified (Table 1), with representation in each of 
the three subfamilies: alpha-herpesviruses, beta-herpesviruses and gamma-herpesviruses [1]. Most of 
the human population carry one or more herpesviruses, for example Epstein-Barr virus (EBV) has 
colonized more than 90% of the adult human population worldwide. 
Primary infection with herpesviruses may be clinically silent or manifest as acute disease that is 
usually followed by establishment of lifelong latent persistence with occasional reactivation. A key 
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component of the virus-host balance during persistent infection is the immune response elicited by the 
host, which includes CD8 and CD4 T cell responses targeting a very broad range of virus antigens [2]. 
In immunocompromised patients, the herpesviruses can be reactivated with a resultant predisposition 
to viral diseases due to the loss of immune control [3–5]. Whilst the potent cellular immune responses 
normally restrict the pathogenic potential of herpesviruses, it is evident that they fail to eliminate the 
virus completely from its host. This implies that herpesviruses have very effective immune evasion 
mechanisms. Strategies for immune-evasion may be broadly defined as passive or active. Passive 
evasion is exemplified by latency, or restricted expression of viral target antigens, rendering the 
infected cells invisible or less visible to the immune system [6]. Active evasion involves viral gene 
products (immunevasins) that interfere with specific immune functions such as antigen presentation; 
one of the earliest reported mechanisms of active evasion by a human herpesvirus was that of  
HSV-encoded ICP47 interacting with and inhibiting the TAP transporter of antigen processing [7–9]. 
It is important to recognise that immune evasion mechanisms are not absolute, but rather they serve to 
blunt the effectiveness of immune responses. In the healthy infected host the establishment of an 
equilibrium between host immune responses and viral evasion mechanisms allows virus persistence 
with minimum pathogenic consequences.  
Table 1. Herpes viruses and their associated diseases. 
Subfamily Virus name Nomenclature Associated diseases 
Alpha-herpesviruses Herpes Simplex-1 HSV-1 or HHV-1 Gingivostomatosis, Cold 
sores, Encephalitis 
 Herpes Simplex-2 HSV-2 or HHV-3 Genital herpes, Cutaneous 
herpes, Encephalitis, 
Meningoencephalitis 
 Varicella zoster virus  VZV or HHV-3 Chickenpox, Shingles 
Beta-herpesviruses Cytomegalovirus HCMV or HHV-5 Mononucleosis, Hepatititis, 
Pneumonitis 
 Human herpesvirus-6  HHV-6 Exanthum subitum, Mild 
febrile illness 
 Human herpesvirus-7 HHV-7 Exanthum subitum, Mild 
febrile illness 
Gamma-
herpesviruses 
Epstein-Barr virus EBV or HHV-4 Mononucleosis, Burkitt’s 
lymphoma, post-transplant 
lymphoproliferative 
syndrome (PTLD), 
nasopharyngeal carcinoma, 
 Kaposi’s sarcoma-
associated herpesvirus  
KSHV or HHV-8 Kaposi’s sarcoma, primary 
effusion lymphoma, some 
types of multicentric 
Castleman’s disease 
The identification and functional characterisation of immunevasins of herpesviruses targeting the 
major histocompatibility complex class I (MHC-I) antigen presentation pathways has been extensively 
studied (for reviews, see [10–14]). A picture emerges that each member of the herpesviridae family 
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encodes multiple immunoevasins which together target multiple steps of the MHC-I antigen 
presentation pathway. Less well understood, however, are the mechanisms evolved by herpesviruses to 
manipulate the major histocompatibility complex class II(MHC-II) antigen presentation pathways.  
In this review, we will outline and discuss recent developments in the research on the interference by 
herpesvirus immunevasins with MHC-II antigen presentation pathways to CD4 T cells. 
2. Why MHC-II Evasion Is Important 
Historically cytotoxic CD8 T cells have been considered the crucial immune effector cells to 
mediate pathogen clearance by killing the infected host cells. Indeed, the success of adoptive T cell 
therapy for EBV-associated lymphoproliferations in transplant patients [15,16] lended support for this 
view. The role of CD4 T cells in anti-viral immunity was for some time considered as mostly indirect 
by providing help to promote the generation and functions of B cells and CD8 T cells. However, 
evidence is accumulating that many CD4 T cells have cytotoxic functions and other direct antiviral 
roles [17]. This puts a different perspective on the significance of the finding that the presence of CD4 
cells admixed with CD8 cells in the immune T cell infusions used in adoptive immunotherapy of 
transplant patients correlates with improved treatment outcome [18]. 
In animal models of herpesvirus infections, there is strong evidence for CD4 immune T cells 
affording anti-viral protection independently of their traditional helper activities. For example, in the 
case of the MHV68 gamma-herpesvirus mouse model, Stevenson et al. used antibody treatment to 
deplete different T cell subsets to show that the mice can survive MHV68 infection even when the 
CD8 T cell population was greatly diminished, whereas the concurrent removal of both CD4 and CD8 
T cell subsets proved invariably fatal [19]. In a separate study, Christensen et al. showed that CD4  
T cells can be directly antiviral, independently of CD8 T cells or B cells, in MHV68-infected  
mice [20]. In a more recent study by Sparks-Thissen et al. using T-cell receptor (TCR) transgenic mice 
that had CD4 T cells specific for OVA were challenged with the a recombinant MHV68 expressing 
OVA [21], the OVA-specific CD4 T cells were found to limit the acute MHV68 replication and 
prolonged the life of transgenic mice. It was subsequently shown by Stuller et al. that CD4 T cells 
mediate anti-viral control by two independent mechanisms, IFN-γ production and cytotoxicity [22].  
Altogether, these data showed that CD4 T cells can control replication, prevent lethal infection, and 
inhibit the establishment of latency in MHV68 infection. Similarly, in mouse models for HSV 
infection, immune CD4 T cells play an important role in clearance of infectious virus at neural sites 
following HSV-1 infection [23], and can protect mice from lethal infection by HSV-2 when adoptively 
transferred CD4 T cells expressed functional FasL that induces apoptosis of Fas-expressing target cells 
in vitro [24]. CD4 T cell mediated protection in the absence of CD8 T cells and B cells has also been 
described in animal models of infection by VZV [25] and in infections by other virus families, 
including influenza [26], poliovirus [27] and West Nile virus [28].  
In addition to causing acute and chronic infections, the human gamma-herpesviruses EBV and 
KSHV could be oncogenic. Cell growth transformation of human B cells by EBV is achieved with 
remarkable efficiency in vitro, but can be abrogated by the EBV-specific immune T cell memory 
present in the peripheral blood of EBV-positive donors. Whilst there is a large body of evidence 
pointing to the role of cytotoxic CD8 T cells in the inhibition of outgrowth of transformed B cells in 
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this model [29], depletion experiments also revealed a role for CD4 T cells [30]. Subsequent studies 
showed that outgrowth of EBV transformed B cells could also be mediated by EBV-specific CD4 T 
cells primed in vitro by dendritic cells (DCs) from EBV sero-negative donors [31], or by  
EBNA1-, EBNA2-, LMP1- or LMP2-specific CD4 T cell clones generated from EBV sero-positive 
donors [32–34]. Furthermore, taking the advantage of the animal model of MHV-68 oncogenic 
gamma-herpesvirus, Robertson et al. showed that MHV68-specific CD4 T cells, but not CD8 T cells 
can eliminate the tumors that were induced by injection of a MHV68-infected B cell lymphoma  
cell line into T cell–deficient (nude) mice[35]. Taken together, these data showed that virus-specific 
CD4 T cell responses can control gamma-herpesvirus induced lymphocyte growth-transformation 
independently of CD8 T cells.  
2.1. Herpesvirus Infections Generate Broad Range Anti-Viral CD4 T Cell Responses 
The breadth and specificity of herpesvirus-specific CD8 and CD4 T cell responses has been 
extensively studied more than a decade. Below, we summarise the CD4 T cell responses to human 
herpesvirus infections.  
2.1.1. HSV 
Although there were a few prior reports about the CD4 T cell responses to HSV [36,37], a recent 
systematic and genome-wide scan by Koelle’s group [38] provided a more complete picture of the 
repertoire of CD4 T cell responses. In this latter study HSV-1 specific CD4 memory T cells were 
reactivated with UV-killed cell-associated HSV-1. Deploying a near complete collection of HSV-1 
ORF clones to identify the specificity of the polyclonal virus-specific CD4 T cells, it was shown that 
the average number of HSV-1 open reading frames (ORFs) recognized per individual was 22.8 ± 7.0 
(mean ± SD), and 74 unique polypeptide antigen targets were identified. On a population basis, the 
most prevalent CD4 responses were envelope glycoproteins gB1 and gD1, and tegument protein 
VP11/12, encoded by the UL46 gene [38]. 
2.1.2. HCMV 
Sylwester et al. carried out an inclusive screening of CD4 and CD8 T cell responses in  
33 HCMV seropositive donors, with 13,687 overlapping 15 mer peptides covering all 213 known or 
predicted HCMV ORFs [39]. With regards to CD4 T cell responses, 5 ORFs (UL55, UL83, UL86, 
UL99, and UL122) were recognized by more than half of the studied subjects, and 40 ORFs were 
recognized by CD4 T cells in at least 4/33 subjects. The immunogenic ORFs span all temporal and 
functional categories. CMV specific responses often accounted for a remarkably high proportion of the 
overall CD4 peripheral blood T cell population, with 10/33 seropositive subjects displaying total 
HCMV-specific CD4 T cell responses that represented ≥20% of their circulating memory repertoire. 
2.1.3. EBV 
Because of the available cell models, T cell responses to EBV have been extensively studied for 
target antigens expressed in ‘latent’ growth-transformed cells as well as those in ‘lytic’ virus-producing 
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cells. In EBV latency, nine viral antigens are expressed, including six Nuclear Antigens (EBNAs), a 
vBCL2 homologue (BHRF1) and two Latent Membrane Proteins (LMP1 and LMP2). CD4 T cell 
responses are broadly targeted across all nine proteins, although up to half of the currently defined 
CD4 epitopes (but not necessarily those eliciting the strongest responses) derive from EBNA1 [2]. 
Many of these CD4 T cells recognize and inhibit the outgrowth of EBV-transformed normal B cells 
(lymphoblastoid cell lines, LCLs) in vitro, and some have cytotoxic function enabling them to directly 
kill LCLs or EBV-positive tumour cell lines such as Burkitt lymphoma lines [34,40–43].  
Whilst EBV-transformed normal LCLs display a predominantly non-productive ‘latent’ infection, 
most such lines contain a minor subpopulation of cells that have spontaneously switched into the lytic 
cycle with sequential expression of two immediate early (IE) genes, about 30 early (E) genes, and 
about 30 late (L) lytic genes. It has long been recognised that some EBV lytic cycle antigens are 
strongly immunogenic for CD4 T cell responses [44,45]. More recently, Long et al. undertook a  
more systematic analysis of CD4 T cell responses to eight lytic proteins in 14 virus-immune  
donors [46], showing that the CD4 T cell response is widely distributed across IE, E, and L antigen 
targets. Remarkably, all the lytic antigen-specific CD4 clones tested had cytotoxic function, with target 
cell killing being associated with cell surface mobilization of CD107a [46]. 
2.1.4. KSHV 
There are few reports describing immune T cell responses to KSHV. Recently, Sabbah et al. 
investigated the magnitude and the specificity of CD4 T cell responses to 4 of the latent antigens that 
are expressed in KSHV-associated primary effusion lymphoma (PEL); LANA, vFLIP, cCyclin, and 
Kaposin [47]. Generally, responses in healthy infected donors to these antigens were very weak 
compared to what is observed with responses to the closely related EBV gamma-herpesvirus, and the 
majority of CD4 T cell clones generated were specific for LANA derived peptides.  
2.1.5. VZV 
VZV-specific CD4 T cells can be detected during acute VZV infection. Several studies have shown 
that VZV-specific CD4 T cells recognize ORF4 [48], glycoprotein I [49], and ORF63 [50]. 
Furthermore, it appears that VZV-specific CD4 T cells circulate at much higher frequencies compared 
to VZV-specific CD8+ T cells [49,51].  
2.1.6. HHV-6 
CD4 T cells responding to HHV-6 were observed at frequencies below 0.1% of total  
T cells, and they can release IFN-γ and IL-10 after stimulation [52].  
2.2. Target Cells Expressing MHC-II and Presenting Peptide 
Normally, MHC class II expression is largely restricted to professional antigen-presenting cells 
(APCs), which potentially limits the protective potential of virus-specific cytotoxic CD4 T cells. 
However, MHC-II expressing professional APCs are natural targets for many herpesviruses;  
for example, B cells are target cells for EBV, KSHV. Furthermore, inflammatory cytokines such  
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3. Mechanisms for Interfering with the MHC-II Antigen Presentation Pathway 
Effector CD4 T cells can be generated during both chronic and acute infection with herpesviruses 
infection, and are important for controlling the infection through both cytotoxic and cytokine-dependent 
mechanisms. How then do these viruses modulate MHC-II antigen presentation pathways to avoid 
complete elimination and to enable them to establish a successful persistent infection? 
3.1. The MHC-II Antigen Presentation Is Inhibited in the Cells Infected with Herpesviruses  
Evidence has accumulated over the past dozen years or so to support the idea that modulation of 
MHC-II presentation is a common feature of all human herpesviruses [59]. In one early report, analysis 
of the distribution of MHC-II expressing cells in skin biopsies taken from individuals with acute 
varicella or herpes zoster showed that MHC-II DR-α transcripts were detected in cells in proximity to 
virus-infected cells but were never detected in the virus-infected cells themselves [60]. An in vitro 
investigation of HCMV infection of the U373-CIITA cell line revealed a virus-mediated 
downregulation of the cell surface MHC-II expression in the absence of any significant change in the 
levels of total cell steady-state MHC-II protein or mRNA [61]. In this study, it was observed that 
MHC-II positive vesicles were retained in an abnormal perinuclear location.  
Importantly, other studies have used functional T cell assays as readout to investigate the biological 
consequences of the modulation of MHC-II expression. Thus, HSV-1 infection of LCL target cells 
substantially reduced their potency as stimulators of antigen-specific CD4 T cell proliferation and 
cytokine release [62]. More recently, we have shown that the MHC-II antigen presentation is impaired 
in LCLs entering EBV lytic cycle [63].  
3.2. Molecular Mechanisms of Herpesviruses’ Modulation of MHC-II Antigen Presentation 
To understand the molecular mechanisms by which herpesviruses modulate MHC-II antigen 
presentation pathway, we will first briefly summarise selected aspects of the process of MHC-II 
antigen presentation (Figure 1) that has been reviewed in more detail elsewhere [64,65]. MHC-II 
molecules are normally co-ordinately expressed under the regulation of the master regulator of 
transcription, CIITA. The MHC-II α-chain, β-chain and invariant chain (Ii; also known as CD74) are 
synthesized and assembled in the endoplasmic reticulum (ER), where the association of CD74 with the 
αβ dimer prevents premature binding of peptides. A cytosolic di-leucine-targeting motif of CD74 
directs MHC-II complexes to the endocytic pathway, either directly from the trans-Golgi network or 
via rapid internalization from the cell surface. Proteases within a special endosome called the MHC II 
compartment cleave the CD74 to enable peptide binding within the HLA class II peptide-binding groove. 
This process requires the involvement of chaperones, HLA-DM and HLA-DO. Stable MHC-II/peptide 
complexes are then presented on the cell surface, where they can be recognized by CD4 T cells.  
3.2.1. Targeting CIITA, the Master Regulator of MHC Class II Gene Expression 
CIITA is a transcriptional co-activator that lacks intrinsic DNA-binding function. It enhances 
transcription of MHC class II genes through interacting with transcription regulatory proteins,  
forming a stable enhanceosome that can bind to the regulatory module of the promoter of MHC-II 
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molecules [66]. CIITA would therefore appear to be a vulnerable target for viral modulation of  
MHC-II gene expression.  
Using the EBV positive tumour cell line Raji, Li et al. demonstrated that the EBV-encoded IE 
protein, BZLF1, which is the master regulator of EBV lytic cycle, can bind to the CIITA promoter and 
strongly inhibit the transcription and constitutive expression of CIITA molecules [67]. This inhibition 
of CIITA, in turn can downregulate MHC-II DR expression. Another herpes virus protein vIRF3 from 
KSHV, which is expressed in latently infected primary effusion lymphoma (PEL) cells also inhibits the 
transcription of CIITA and suppresses the expression of MHC-II molecules [68]. In that study 
knockdown of vIRF-3 in KSHV-positive PEL cell lines using small interfering RNA (siRNA) 
technology resulted in increased MHC II levels. By using a more detailed luciferase reporter assay, the 
inhibition by vIRF3 was mapped to the IFN-γ responsive CIITA promoters, PIV and PIII.  
MHC-II molecules are constitutively expressed on professional APC cells, but the expression can 
be induced on other cells by IFN-γ through the induced transcription of CIITA [66]. In this context, 
HCMV infection of U373 MG cells caused a 13.5-fold reduction in the level of CIITA transcripts 
induced following treatment with IFN-γ, with a concordant inhibition of induced HLA-DR  
synthesis [69]. This inhibition of CIITA was traced to a defect downstream of IFN-γ induced STAT1 
phosphorylation and nuclear translocation, although the viral gene responsible was not identified.  
It was also shown that the suppression of DR synthesis inhibits recognition by CD4 T cells specific for 
the major immediate-early protein, IE1. Importantly, these effects of HCMV were abrogated when the 
U373 MG target cells were transfected with a CIITA expression plasmid prior to infection with 
HCMV. Similarly to that observed with HCMV, VZV infection of human foreskin fibroblasts can 
prevent the IFN-γ induced CIITA expression, and consequently inhibit the transcription and expression 
of MHC-II molecules [60].  
3.2.2. Targeting Transport of DR 
Correct transport of DR is essential for the MHC-II molecules to present the right peptides. The first 
reported identification of a viral inhibitor of the MHC-II pathway was the HCMV-encoded protein 
US2, which causes the degradation of MHC-I [70] and also of DR-α and DM-α, two essential proteins 
in the MHC-II antigen presentation pathway [71]. The latter study by Johnson’s group used an 
inducible replication-defective adenovirus vector expressing US2 to infect and induce the US2 
expression in U373-CIITA cells. By radiolabeling and immunoprecipitation experiments, US2 was 
shown to bind MHC-II molecules, including DR-α, DR-β and CD74. A rapid loss of the MHC-II 
molecules, especially DR-α and DM-α, was observed with US2 expression, which could be reversed 
by proteasome inhibitors. It was hypothesized that the US2 glycoprotein can recognize the shared 
protein structures but not amino-acid sequence in these distinct MHC-II molecules. Finally, by using 
functional CD4 T cells, they showed that expression of US2 reduced the ability of cells to present 
antigen to CD4 T cells. Subsequent studies showed that the C-terminal domain of US2 plays an 
essential role in the degradation process [72,73]. Using in vitro assay based on recombinant protein, 
Gewurz et al. could not confirm the association of US2 with DR and DM, raising the possibility that 
the mechanism of US2 action is cell-type dependent [74].  
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The HCMV genome region encompassing US2-US11 region encodes four homologous 
glycoproteins, US2, US3, US6, and US11, all of which can modulate the MHC-I antigen presentation 
pathway. Johnson’s group that first reported US2 as MHC-II evasion protein also subsequently 
examined seven glycoproteins of the US2-US11 gene cassette for possible effects on the MHC-II 
antigen presentation pathway, using replication-defective adenovirus vectors and functional CD4 T 
cell assays. In addition to US2, they found that US3 also can inhibit recognition of target cells by CD4 
T cells [75]. By radiolabeling and immunoprecipitation methods, US3 was found to not affect the 
synthesis, stability, nor Golgi transport of MHC-II proteins but could bind to MHC-II DR αβ 
complexes in the ER and reduce their binding with CD74. So in the US3 expressing cells, the MHC-II 
αβ complexes can move normally from the ER to the Golgi, but were not sorted efficiently to the 
MHC-II loading compartment. As a consequence, formation of peptide-loaded MHC-II complexes was 
reduced. It was postulated that by acting through different molecular mechanisms, US2 and US3 may 
cooperate in the context of natural HCMV infection to inhibit MHC-II mediated presentation of viral 
antigen to CD4 T cells. 
Söderberg-Nauclér’s group independently demonstrated that HCMV-infected macrophages also 
exhibited a reduced expression of MHC-II molecules, which was mediated by 2 different mechanisms, 
at an early (1 day after infection) and at a late (4 days after infection) time point after infection [76]. 
Infection with a mutant HCMV-RV670, that is deleted for US1-9 and US11, substantially impaired the 
late effect; implicating a role for one or several genes in the US2-US11 region. The early effect on 
MHC-II expression was retained by UV-inactivated virus and by the deletion mutant HCMV, 
suggesting that a virion component may be responsible. One possible candidate is pp65, as the surface 
expression of HLA-DR was not reduced on cells infected with RVAD65, a mutant lacking pp65 
protein [77]. HCMV infection of cells usually results in accumulation and degradation of HLA-DR in 
vacuoles or lysosomes near the nucleus, but this phenomenon was not observed in cells infected with 
the pp65-deficient mutant virus.  
The binding of viral gene products to DR molecules and subsequent perturbation of transport is not 
restricted to HCMV. Using a bioinformatics approach, Sievers et al. identified a sequence in gB  
from HSV-1 (strain 17) that is identical to the highly conserved HLA-DR binding motif in human 
CD74 [78]. Confirmation of the significance of this sequence identity was provided experimentally by 
the physical association of HSV-1 gB with three MHC-II DR allotypes, including DR1, DR3 and DR4.  
Using the HSV-1 infected B cell model, the Koch group showed that HSV-1 not only can bind to 
DR but also can bind to DM independently of the DR expression [79]. Furthermore, they showed that 
HSV-1-encoded gB can compete with CD74 for binding to MHC-II heterodimers. Both gB-associated 
DR and DM heterodimers can be exported from the ER to Golgi compartments. But the association of 
DR with HSV-1 gB changes the intracellular localization and hence reduces the DR expression on the 
cell surface. More recent work from the same group showed that the gB/DR complexes are resistant to 
Endo H treatment and are free of invariant chain, CD74. This leads to another hypothesis that HSV-1 
gB associates with DR not in the ER, but rather after CD74 is released from DR [80]. The same study 
also showed that DR and gB are contained in morphologically altered endocytic vesicles containing 
the late endosomal marker CD63. Furthermore, the gB/DR complexes were detected in exosomes, and 
elevated amounts of DR and CD63 were released into exosomes following expression of gB.  
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It was therefore concluded that HSV-1 gB reduces the surface expression of DR by hijacking DR away 
from its normal transport route to the cell surface. 
3.2.3 Targeting CD74 
CD74 is the invariant polypeptide chain involved in the transport of MHC-II molecules, and 
facilitates appropriate peptide loading to MHC-II complexes in the endolysosomal vesicles [65].  
Its importance for antigen presentation is illustrated by the demonstration that knock-down of CD74 
expression through siRNA technology can suppress the recognition by specific CD4 T cells [63].  
It now appears that CD74 is a common target of viruses to modulate MHC-II antigen presentation. In a 
study of HSV-1 infection of B cells, Neumann et al. evaluated the total amount of CD74, DR, and  
DM at different times after HSV-1 infection, and showed that the expression of CD74 was 
dramatically reduced in infected cells from 18 h post-infection, falling to less than 15% at 64 h  
post-infection compared to uninfected cells, while the total cell levels of HLA-DR and -DM remained 
unaffected [79]. However, the level of SDS-stable MHC-II complexes, which represents the fraction of 
peptide-loaded MHC-II complexes was greatly reduced in the infected cells compared with uninfected 
cells. Together, these observations hint that the loss of CD74 expression leads to impaired peptide 
loading to the MHC-II complexes in the HSV-1-infected cells, with consequent impairment of MHC-II 
antigen presentation.  
Very recently we showed that EBV-encoded BZLF1 also targets CD74 to help the virus evade CD4 
T cell recognition [63]. In functional CD4 T cell assays, BZLF1 was found to interfere with 
recognition by immune CD4 T cells. This impaired T cell recognition occurred in the absence of a 
reduction in the expression of surface MHC-II DR, but correlated with a marked downregulation of 
surface CD74 on the target cells. The surface CD74 downregulation by BZLF1 is mediated through an 
as yet unknown post-transcriptional mechanism that is distinct from previously reported effects of 
BZLF1 on the CIITA promoter. Interestingly, in addition to being a chaperone for MHC-II complex, 
CD74 also functions as a surface receptor for macrophage Migration Inhibitory Factor and  
enhances cell survival through transcriptional upregulation of Bcl-2 family members [81,82]. The  
immune-evasion function of BZLF1 therefore comes at a cost of induced toxicity. However, this 
toxicity can be overcome by expression of another E gene, BHRF1, which is a BCL-2 family 
homologue [63].  
3.2.4. Manipulation of T Cell Receptor (TCR) Recognition 
The herpesviruses have evolved mechanisms to modulate MHC-II antigen presentation even after 
the MHC-II peptide complex reached the cell surface. The best studied example of this is the  
EBV-encoded BZLF2 protein (gp42) which also has a critical role in the binding and entry of EBV 
during infection of B cells by EBV [83,84]. In mixed lymphocyte culture assays of T cell function, 
gp42 can inhibit antigen-driven PBMC proliferation. Both the viral entry function and the immune-evasion 
function of gp42 derive from its ability to bind to the MHC-IIDR β-chain, which occurs in a domain 
that participates in the formation of peptide binding pockets [85]. By using MHC-II expressing human 
melanoma cells, a more detailed biochemistry study showed that EBV-encoded gp42 did not alter 
HLA-DR surface expression, nor its intracellular transport and maturation. But it was confirmed in a B 
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cell model system that EBV encoded gp42 does reduce the ability of target cells to activate specific 
CD4 T Cells [86]. The underlying mechanism involves abolition of interactions between TCR on the CD4 
T cell with MHC-II peptide complexes in the presence of gp42; crystal structure studies revealed that EBV 
gp42 sterically competes with TCR V-α domains [87]. There are two forms of gp42, a full-length type II 
membrane protein and a truncated soluble form, both of which can be detected in an EBV-producing 
Burkitt’s lymphoma cell line. Interestingly, this soluble form gp42 itself is sufficient to inhibit MHC-II 
antigen presentation in functional CD4 T cell assay [88]. This interference of TCR interaction with 
MHC-II complex by EBV gp42 is a novel mechanism to modulate MHC-II antigen presentation. 
3.2.5. Other Mechanisms of Manipulation of MHC-II Pathway  
Notwithstanding the above mentioned specific immune evasion strategies of herpesviruses, there 
are other important but more general mechanisms of evasion from CD4 T cell responses. The first is 
global host protein synthesis shutoff following entry into lytic cycle, which is a feature of alpha- and 
gamma-herpesviruses. It can diminish antigen presentation on both the MHC-I and MHC-II antigen 
presentation pathways by limiting the availability of newly synthesised MHC molecules and their 
chaperones. The viral genes responsible are not homologous across the herpesvirus subfamilies. The first 
virus host shutoff (vhs) gene to be identified was UL41 of HSV-1 [89], which has endoribonuclease 
enzyme functions that effect host shutoff by decreasing the half-life of mRNAs [90,91]. Beta- and 
gamma-herpesviruses do not contain UL41 homologous genes, although gamma-herpesviruses encode 
enzymes that serve as vhs equivalents; for EBV, the relevant gene is BGLF5 [92]and for KSHV it is 
SOX [93]. Interestingly, the vhs proteins from gammaherpesviruses, are bifunctional proteins that  
were first identified as DNase/alkaline exonuclease enzymes [94,95] that are conserved across  
all herpesvirus families but which in gammaherpesviruses have evolved additional mRNase  
functions [96,97]. The degradation of mRNA induced by these viral proteins blocks the synthesis of 
MHC-II molecules, which is reflected by reduced levels of these MHC-II complexes on the cell 
surface. By using UL41 knockout HSV-1 virus, one study confirmed that UL41 can shut off the 
synthesis of MHC-II molecules and partly contribute to the downregulation of surface expression of 
MHC-II molecules in the whole virus context [98]. Although it has yet to be tested that this vhs protein 
or that of the gamma-herpesviruses can inhibit the recognition by CD4 T cells, in light of their effect 
on CD8 T cell recognition [95] it is reasonable to presume that the effect on MHC-II expression could 
lead to escape from CD4 T cell recognition.  
Another feature shared by many herpesviruses, including HCMV [99] and EBV [100] is that they 
encode viral homologues of interleukin 10 (vIL-10), which is known for its function of downregulating 
the cell surface MHC-II expression by preventing them reaching the cell surface [101]. Indeed, treating 
monocytes with recombinant CMV IL-10 can reduce the surface expression of MHC class II by about 
threefold compared with control mock-treated cells [102]. Recently, one study showed that infection of 
human primary endothelial cells with KSHV, which does not encode a vIL10 homologue, inhibits 
IFN-γ-induced expression of the MHC-II molecule at the transcriptional level; this effect was mediated 
by soluble factors, including cytokines released from the KSHV-infected endothelial cells [103].  
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4. Conclusion 
Persistent lifelong infection by herpesviruses depends on the balance between host immune 
responses and viral immune evasion. On the one hand, herpesvirus infections elicit very strong T cell 
responses, on the other hand the herpesviruses have evolved mechanisms to interfere with MHC 
antigen presentation. Recent studies have demonstrated the capacity of herpesviruses to modulate 
MHC-II antigen presentation by targeting multiple points in the antigen processing pathway, and to 
impair recognition by virus-specific CD4 T cells. In addition, a number of herpesvirus gene products 
responsible for this modulation have been identified and characterized. Collectively these studies have 
enhanced our understanding of the normal biology of herpesvirus persistence, and have the potential to 
inform immunotherapeutic strategies to combat the pathogenic effects of these viral infections. 
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